Fig 3 - by Nida Mansoora (11648641)

Subjects:

Fig 4 - by Nida Mansoora (11648641)

Subjects:

Fig 1 - by Nida Mansoora (11648641)

Subjects:

Effect of different treatments on ionic contents like sodium, calcium, potassium, phosphorous and soluble proteins constituents of two wheat genotypes (Markaz 19 and Ujala 16) afte... by Nida Mansoora (11648641)

Subjects:

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Subjects:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Subjects:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Empirical Bayes estimates of parameter <i>μ</i>. by Guillaume Lingas (9955528)

Subjects:

Model building procedure. by Guillaume Lingas (9955528)

Subjects:

Ratio of titers to viral load at the time of peak viral load in cynomolgus macaques infected with Lassa (top) or Ebola (bottom) virus. by Guillaume Lingas (9955528)

Subjects:

Evolution of target cells TC, productive infected cells I2, refractory cells R and immune effector F. by Guillaume Lingas (9955528)

Subjects:

Parameters distribution using model averaging (Median, 95% CI). by Guillaume Lingas (9955528)

Subjects:

Individual fits of viral load (plain lines) and viral titers (dashed line) for best model considered (<i>κ</i> = 5). by Guillaume Lingas (9955528)

Subjects:

Description of viral kinetics. by Guillaume Lingas (9955528)

Subjects:

Post-mortem RNA viral load by organ. by Guillaume Lingas (9955528)

Subjects: